- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
TriSalus Life Sciences Inc (TLSI)
NASDAQ
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.672
5.756
52 wk Range
2.200
7.950
TLSI Earnings
View the latest TriSalus Life Sciences earnings results, revenue figures, and TriSalus Life Sciences earning report, including the TriSalus Life Sciences earnings dates and reported performance.
Latest Release
Aug 07, 2026
EPS / Forecast
-0.16 / -0.15
Revenue / Forecast
11.41M / 10.79M
All numbers in USD
TriSalus Life Sciences Inc Earnings Call Summary for Q2/2026
- TriSalus Q2 revenue hit $11.4M, beating $10.79M forecast by 5.7%; gross margin improved 290bps to 86.8% year-over-year.
- Adjusted EBITDA loss widened to $7.1M from $5.3M as sales/marketing spend surged 58% to $11.4M amid sales force expansion.
- Company maintained 2026 revenue guidance of $54M-$57M, implying 19%-26% growth; expects sequential improvement through year-end.
- New office-based lab G-code reimbursement could expand TriNav access across multiple embolization procedures beyond core liver market.
- Stock rose 5.41% to $4.87 in regular session but slipped 2.11% after-hours; shares down 34% YTD despite revenue beat.
Last Updated: 2026-08-06, 05:14 p/m
Read Full TranscriptFAQ
What Is TriSalus Life Sciences's Earnings Per Share (TTM)?
The TriSalus Life Sciences EPS (TTM) is -1.175.
When Is The Next TriSalus Life Sciences Earnings Date?
TriSalus Life Sciences will release its next earnings report on Nov 12, 2026.
What Is TriSalus Life Sciences’s Revenue Forecasts For Upcoming Quarters?
TriSalus Life Sciences’s revenue forecast is 14.62M.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.